Heidelberg Pharma's Nine-Month Update for 2025

Heidelberg Pharma AG has reported on its progress over the first nine months of 2025. The company’s lead anticancer drug candidate, HDP-101, continues to display a favorable safety profile, with a clinical trial entering its ninth cohort at an increased dose. However, a delay in a crucial milestone payment necessitated significant cost-saving measures, including a 75% workforce reduction and a sharpened focus on HDP-101. This strategic shift comes as new promising clinical data was presented at the International Myeloma Society Annual Meeting.

The delay in the expected $70 million payment from HealthCare Royalty, linked to FDA approval of a partner's diagnostic agent, has put pressure on Heidelberg Pharma’s operations. Consequently, the company revised its financial outlook, predicting lower revenues and increased operating expenses compared to previous forecasted figures. Liquidity remains a challenge, potentially threatening the company's continuity.

Despite this, HDP-101 shows clinical promise, especially among heavily pretreated patients, signaling hope for the therapeutic potential of this candidate in multiple myeloma treatment.